The cost of Guangzhou Pharmaceutical staying in Kangmei does not exceed 6.5 billion. Because on June 5438+ 10/0, 2022, GPHL invested no more than 6.5 billion yuan in Kangmei Pharmaceutical through Shennong Partnership to participate in the restructuring of Kangmei Pharmaceutical. According to the reorganization plan, Shennong Partnership, which consists of Guangzhou Pharmaceutical Group Co., Ltd., Guangzhou Shennong Chinese Medicine Development Co., Ltd., Guangdong Cai Yue Industrial Investment Fund Partnership, Guangdong Hengjian Asset Management Co., Ltd., Jieyang Jinye Development Co., Ltd. and some social capital, will participate in the company reorganization of Kangmei Pharmaceutical. Therefore, the cost of Guangzhou Pharmaceutical staying in Kangmei does not exceed 6.5 billion.